肝动脉化疗栓塞联合灌注三氧化二砷治疗原发性肝癌初步观察

Efficacy of hepatic artery infusion of arsenic trioxide in treatment of hepatocellular carcinoma

探讨三氧化二砷肝动脉灌注治疗原发性肝癌的临床疗效。对62例和56例原发性肝癌患者分别采用常规药物联合三氧化二砷和单纯常规药物介入治疗,分析治疗效果。结果常规药物联合三氧化二砷组1年生存率优于单纯常规药物组,P=0·017,P<0·05,半年生存率及近期疗效差异无统计学意义,P>0·05。初步研究结果提示,原发性肝癌患者肝动脉常规药物联合三氧化二砷介入治疗能提高1年生存率。

The objective of this study was to investigate the efficacy of hepatic artery infusion of arsenic trioxide in the treatment of hepatocellular carcinoma. Sixty-two cases of hepatocellular carcinoma treated by routine medicines combined with arsenic trioxide and 56 cases of hepatocellular carcinoma that routine medicines were analyzed after transarterial chemoemboliztion. The one-year survival rate was higher in experimental group than that in the control group, and the half a year survival rate and recent efficacy were not significantly different between the two groups. In conclusion, combination of arsenic trioxide with transcatheter arterial chemoemboliztion can improve one-year survival rate of hepatocellular carcinoma.